|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8-9
|
|
pubmed:dateCreated |
2003-11-11
|
|
pubmed:abstractText |
During the two least decades, the field of tumor immunology has met an expansion of knowledge about the molecular and cellular bases of immune regulation. The identification of cancer antigens has been of critical importance and cancer vaccine is at present a very fast moving field. However, the immunotherapy approaches in cancer are of modest success. This is mainly due to the capacity of tumor cells to escape from immunological detection and to resist to cell mediated cytotoxicity. We will discuss some mechanisms associated with the acquisition of this tumor resistance and the alteration of T cell function and how cancer profiling through genomics approaches may help to reconceptualize immunotherapy strategies.
|
|
pubmed:language |
fre
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD95,
http://linkedlifedata.com/resource/pubmed/chemical/FASLG protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Fas Ligand Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/NF-kappa B,
http://linkedlifedata.com/resource/pubmed/chemical/Perforin,
http://linkedlifedata.com/resource/pubmed/chemical/Pore Forming Cytotoxic Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, KIR,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Natural Killer Cell,
http://linkedlifedata.com/resource/pubmed/chemical/Serine Endopeptidases,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0007-4551
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
John Libbey Eurotext 2003
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
90
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
686-94
|
|
pubmed:dateRevised |
2009-11-11
|
|
pubmed:meshHeading |
pubmed-meshheading:14609757-Antigens, CD95,
pubmed-meshheading:14609757-Apoptosis,
pubmed-meshheading:14609757-Fas Ligand Protein,
pubmed-meshheading:14609757-Humans,
pubmed-meshheading:14609757-Immunologic Surveillance,
pubmed-meshheading:14609757-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:14609757-Membrane Glycoproteins,
pubmed-meshheading:14609757-NF-kappa B,
pubmed-meshheading:14609757-Neoplasms,
pubmed-meshheading:14609757-Perforin,
pubmed-meshheading:14609757-Pore Forming Cytotoxic Proteins,
pubmed-meshheading:14609757-Receptors, Immunologic,
pubmed-meshheading:14609757-Receptors, KIR,
pubmed-meshheading:14609757-Receptors, Natural Killer Cell,
pubmed-meshheading:14609757-Serine Endopeptidases,
pubmed-meshheading:14609757-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:14609757-Tumor Escape,
pubmed-meshheading:14609757-Tumor Suppressor Protein p53
|
|
pubmed:articleTitle |
[Tumor/cytotoxic effector cross-talk in the control of tumor susceptibility to lysis].
|
|
pubmed:affiliation |
Inserm U487, IFR 54, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif, France.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
